ÇAVA HEALTHCARE Inc.
Chronic and acute inflammation and poor immune function are at the core of many diseases. ÇAVA is addressing this unmet healthcare challenge through isolation and characterization of novel medically useful compounds from plants, development and validation of novel biomarkers for disease, and application of cutting-edge technologies to reverse inflammation and restore immune function to achieve optimal health.
ÇAVA is focused on enhancing optimal health by predicting, preventing and alleviating diseases.
On July 9th 2019 we announced that ÇAVA Healthcare Inc. has entered into an agreement with multiple inventors, including Professor Raymond Andersen and Professor Wilf Jefferies of the University of British Columbia (Vancouver) and Professor Dara Dickstein of the Uniformed Services University of the Health Sciences (Washington, DC), to acquire a portfolio of five patent families comprised of patents and patent applications filed worldwide. Under the Agreement, the Company will acquire 100% of the legal and beneficial interest in the patents.
The patent portfolio relates to translating new therapies and biomarkers for disease in the areas of:
Our News and Filings can be found on sedar.com
Common pharmaceuticals can sometimes be replaced by natural products that function in the same way, but which are more readily tolerated by the body and/or have fewer side effects, e.g., replacing opioids for relief of chronic pain.
ÇAVA's path to new drug discovery begins with extracts from high quality plant sources and other biomasses of known origin. The most promising extracts are purified into isolates, which are then screened for pharmacological activity (e.g., against target diseases). The most promising candidate compounds from screening are then forwarded for more detailed testing including, where appropriate, clinical trials.
ÇAVA research scientists produce extracts and isolates in-house using state-of-the-art separation techniques. After analysis in our laboratories, the materials are further characterized using highly sensitive analytical methods such as liquid chromatography - mass spectrometry (LC-MS) and tandem mass spectrometry (MS-MS). This approach allows rapid isolation and identification of new phytochemicals.
In addition to creating extracts and isolates for its own use, ÇAVA may sometimes undertake toll processing for pharmaceuticals, nutraceuticals and essential oils. This will provide revenue to support research and development.
Chief Science Officer
Chief Operating Officer
Chairman & Chief Science Officer
Chief Executive Officer
Chief Operating Officer